In other words, we still don’t know how a modulated expression of P2X7 is directly linked to ALS pathology and, moreover, why AXX13 therapeutically failed, despite a potency profile higher than AXX71, and a more frequent administration protocol. The gene discussed is P2RX7; the disease is amyotrophic lateral sclerosis.